Israel - English - Ministry of Health

j-c health care ltd - ibrutinib - film coated tablets - ibrutinib 280 mg - ibrutinib - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.

Israel - English - Ministry of Health

j-c health care ltd - ibrutinib - film coated tablets - ibrutinib 420 mg - ibrutinib - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.

Israel - English - Ministry of Health

j-c health care ltd - ibrutinib - film coated tablets - ibrutinib 560 mg - ibrutinib - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - fludarabine phosphate - concentrate for solution for injection/infusion - 25 milligram(s)/millilitre - purine analogues; fludarabine

European Union - English - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents - mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (bcll) for whom fludarabine combination chemotherapy is not appropriate.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - fludarabine phosphate - powder for solution for injection - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - fludarabine phosphate - solution for injection - 25mg/1ml

United States - English - NLM (National Library of Medicine)

eagle pharmaceuticals, inc - bendamustine hydrochloride (unii: 981y8sx18m) (bendamustine - unii:9266d9p3pq) - belrapzo is indicated for the treatment of patients with chronic lymphocytic leukemia. efficacy relative to first line therapies other than chlorambucil has not been established. belrapzo is indicated for the treatment of patients with indolent b-cell non-hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. belrapzo is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol. [see warnings and precautions (5.4)] risk summary in animal reproduction studies, intraperitoneal administration of bendamustine to pregnant mice and rats during organogenesis at doses 0.6 to 1.8 times the maximum recommended human dose (mrhd) resulted in embryo-fetal and/or infant mortality, structural abnormalities, and alterations to growth (see data ). there are no available data on bendamustine hydrochloride use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data bendamustine hydrochloride was intraperitoneally administered once to mice from 210 mg/m2 (approximately 1.8 times the mrhd) during organogenesis and caused an increase in resorptions, skeletal and visceral malformations (exencephaly, cleft palates, accessory rib, and spinal deformities) and decreased fetal body weights. this dose did not appear to be maternally toxic and lower doses were not evaluated. repeat intraperitoneal administration of bendamustine hydrochloride in mice on gestation days 7 to 11 resulted in an increase in resorptions from 75 mg/m2 (approximately 0.6 times the mrhd) and an increase in abnormalities from 112.5 mg/m2 (approximately 0.9 times the mrhd), similar to those seen after a single intraperitoneal administration. bendamustine hydrochloride was intraperitoneally administered once to rats from 120 mg/m2 (approximately the mrhd) on gestation days 4, 7, 9, 11, or 13 and caused embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. a significant increase in external (effect on tail, head, and herniation of external organs [exomphalos]) and internal (hydronephrosis and hydrocephalus) malformations were seen in dosed rats. risk summary there are no data on the presence of bendamustine hydrochloride or its metabolites in either human or animal milk, the effects on the breastfed child, or the effects on milk production. because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with belrapzo, and for 1 week after the last dose. belrapzo can cause embryo-fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . pregnancy testing pregnancy testing is recommended for females of reproductive potential prior to initiation of treatment with belrapzo [see use in specific populations (8.1)] . contraception females advise female patients of reproductive potential to use effective contraception during treatment with belrapzo and for 6 months after the last dose. males based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with belrapzo and for 3 months after the last dose [see nonclinical toxicology (13.1)] . infertility based on findings from clinical studies, belrapzo may impair male fertility. impaired spermatogenesis, azoospermia, and total germinal aplasia have been reported in male patients treated with alkylating agents, especially in combination with other drugs. in some instances spermatogenesis may return in patients in remission, but this may occur only several years after intensive chemotherapy has been discontinued. advise patients of the potential risk to their reproductive capacities. based on findings from animal studies, belrapzo may impair male fertility due to an increase in morphologically abnormal spermatozoa. the long-term effects of belrapzo on male fertility, including the reversibility of adverse effects, have not been studied [see nonclinical toxicology (13.1)] . safety and effectiveness in pediatric patients have not been established. safety, pharmacokinetics and efficacy were assessed in a single open-label trial (nct01088984) in patients aged 1 to 19 years with relapsed or refractory acute leukemia, including 27 patients with acute lymphocytic leukemia (all) and 16 patients with acute myeloid leukemia (aml). bendamustine hydrochloride was administered as an intravenous infusion over 60 minutes on days 1 and 2 of each 21-day cycle. there was no treatment response (cr+ crp) in any patient. the safety profile in these patients was consistent with that seen in adults, and no new safety signals were identified. the pharmacokinetics of bendamustine in 43 patients, aged 1 to 19 years (median age of 10 years) were within range of values previously observed in adults given the same dose based on body surface area. no overall differences in safety were observed between patients ≥65 years of age and younger patients. efficacy was lower in patients 65 and over with cll receiving bendamustine hydrochloride based upon an overall response rate of 47% for patients 65 and over and 70% for younger patients. progression free survival was also longer in younger patients with cll receiving bendamustine (19 months vs. 12 months). no overall differences in efficacy in patients with non-hodgkin lymphoma were observed between geriatric patients and younger patients. do not use belrapzo in patients with creatinine clearance (clcr) < 30 ml/min [see clinical pharmacology (12.3)] . do not use belrapzo in patients with ast or alt 2.5-10 × upper limit of normal (uln) and total bilirubin 1.5-3 × uln, or total bilirubin > 3 × uln [see clinical pharmacology (12.3)]

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

schmidt biomedtech sdn bhd - azathioprine -

United States - English - NLM (National Library of Medicine)

slayback pharma llc - bendamustine hydrochloride (unii: 981y8sx18m) (bendamustine - unii:9266d9p3pq) - vivimusta is indicated for the treatment of adult patients with chronic lymphocytic leukemia. efficacy relative to first line therapies other than chlorambucil has not been established. vivimusta is indicated for the treatment of adult patients with indolent b-cell non-hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. vivimusta is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, dehydrated alcohol, or monothioglycerol [see warnings and precautions (5.4)] risk summary in animal reproduction studies, intraperitoneal administration of bendamustine to pregnant mice and rats during organogenesis at doses 0.6 to 1.8 times the maximum recommended human dose (mrhd) resulted in embryo-fetal and/or infant mortality, structural abnormalities, and alterations to growth (see data). there are no available data on bendamustine hydrochloride use